AMPH supply chain intelligence for Amphastar Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Amphastar Pharmaceuticals, Inc. (AMPH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NANJING-HANXIN-PHARMACEUTICAL-TECHNOLOGY-CO-LTD | NANJING-HANXIN-PHARMACEUTICAL-TECHNOLOGY-CO-LTD | 92% | Amphastar is also required to make payments to Hanxin consisting of up to $14 million in development milestone payments and up to $75 million in sales milestone payments |
| NANJING-LETOP-BIOTECHNOLOGY-CO-LTD | NANJING-LETOP-BIOTECHNOLOGY-CO-LTD | 92% | Pursuant to the Supply Agreement, Letop will manufacture and deliver chemical intermediates ("Intermediates") for ANP according to the requirements of the purchase orders confirmed by Letop |
| ARMSTRONG-PHARMACEUTICALS-INC | ARMSTRONG-PHARMACEUTICALS-INC | 90% | Armstrong Pharmaceuticals, Inc. a wholly-owned subsidiary of the Amphastar |
| HONG-KONG-GENREACH-LIMITED | HONG-KONG-GENREACH-LIMITED | 90% | Hong Kong Genreach Limited a wholly-owned subsidiary of Hanxin |
| AMPHASTAR-NANJING-PHARMACEUTICALS-INC | AMPHASTAR-NANJING-PHARMACEUTICALS-INC | 85% | Amphastar Nanjing Pharmaceuticals, Inc., the Chinese subsidiary of Amphastar |
| CONTRACT-MANUFACTURING-ORGANIZATION | CONTRACT-MANUFACTURING-ORGANIZATION | 80% | depends on a contract manufacturing organization, or CMO, for the supply of BAQSIMI ® |
| CAH | Cardinal Health, Inc. | 72% | al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxyprogesterone for Amphastar’s current products, and we plan to have ANP manufacture A… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from CAH graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from CAH grap… |
| HALO | Halozyme Therapeutics, Inc. | 72% | Reciprocal relationship from HALO graph: nce Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including o… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY graph: marketing, selling, and administrative expense, respectively. We receive a roy… |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from MCK graph: Reciprocal relationship from AMPH graph: al. ANP currently manufactures hepari… |
| MCK | McKesson Corporation | 72% | al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxyprogesterone for Amphastar’s current products, and we plan to have ANP manufacture A… |
| MNKD | MannKind Corporation | 72% | Reciprocal relationship from MNKD graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from MNKD graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from MNKD g… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from AMPH graph: of approval of any applications may be more restrictive than our expectations and could affect the marketability of … |
| ORANY | ORANY | 72% | of approval of any applications may be more restrictive than our expectations and could affect the marketability of our products. The FDA also has the authority to revoke or suspend approvals of prev… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HONG-KONG-GENREACH-LIMITED | HONG-KONG-GENREACH-LIMITED | 95% | Hong Kong Genreach Limited a wholly-owned subsidiary of Hanxin |
| HANXIN | HANXIN | 92% | Hanxin will pay to Amphastar a royalty payment of net sales of Licensed Product |
| NANJING-HANXIN-PHARMACEUTICAL-TECHNOLOGY-CO-LTD | NANJING-HANXIN-PHARMACEUTICAL-TECHNOLOGY-CO-LTD | 92% | Hanxin will pay to Amphastar a royalty payment of net sales of Licensed Product |
| AMPHASTAR-NANJING-PHARMACEUTICALS-INC | AMPHASTAR-NANJING-PHARMACEUTICALS-INC | 90% | ANP is entitled to decide the quantity of the Intermediates that it purchases from Letop at its own discretion, and ANP has no obligation to purchase any minimum quantity of the Intermediates from Letop |
| CAH | Cardinal Health, Inc. | 90% | Reciprocal relationship from CAH graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from CAH graph: Reciprocal relationship from AMPH graph: Cardinal Health 14 % 12 % 19 % 20 % |
| CAH | Cardinal Health, Inc. | 90% | al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxyprogesterone for Amphastar’s current products, and we plan to have ANP manufacture A… |
| CENCORA | CENCORA | 90% | Cencora 25 % 28 % 21 % 21 % |
| MCK | McKesson Corporation | 90% | al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxyprogesterone for Amphastar’s current products, and we plan to have ANP manufacture A… |
| MCK | McKesson Corporation | 90% | Reciprocal relationship from MCK graph: Reciprocal relationship from AMPH graph: al. ANP currently manufactures heparin sodium for our enoxaparin product, isoproterenol, hyaluronidase, and medroxypro… |
| HANXIN-PHARMACEUTICAL-TECHNOLOGY-CO-LTD | HANXIN-PHARMACEUTICAL-TECHNOLOGY-CO-LTD | 85% | y, and royalty payments of 5 % on net sales, not to exceed a maximum annual amount of $ 7.5 million each calendar year and a maximum accumulated amount of $ 60.0 million for corticotropin. Hanxin wil… |
| NANJING-CHENGONG-PHARMACEUTICAL-CO-LIMITED | NANJING-CHENGONG-PHARMACEUTICAL-CO-LIMITED | 85% | t have any receivables from Genreach. BAQSIMI ® Distribution Agreement with Nanjing Chengong Pharmaceutical Co., Limited. In October 2025, the Company entered into a distribution agreement with N… |
| HALO | Halozyme Therapeutics, Inc. | 72% | Reciprocal relationship from HALO graph: nce Marketplaces, has substantial power to implement policy changes or demonstration projects that can quickly and significantly affect how drugs, including o… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY grap… |
| MNKD | MannKind Corporation | 72% | Reciprocal relationship from MNKD graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from MNKD graph: Reciprocal relationship from AMPH graph: Reciprocal relationship from MNKD g… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from AMPH graph: itive products may have an adverse effect on our market share, revenue and gross profit from our products. Similarly… |
| ORANY | ORANY | 72% | itive products may have an adverse effect on our market share, revenue and gross profit from our products. Similarly, we will face significant competition for our proprietary product candidates. Our … |
| NANJING-ANJI-BIOTECHNOLOGY-CO-LTD | NANJING-ANJI-BIOTECHNOLOGY-CO-LTD | 62% | se commencement date and the measurement of lease liabilities is based on the present value of lease payments over the lease term. Lease terms are generally based on their initial non-cancelable term… |
| NANJING-LETOP-BIOTECHNOLOGY-CO-LTD | NANJING-LETOP-BIOTECHNOLOGY-CO-LTD | 62% | g agreements with Hanxin and its subsidiaries, whereby Hanxin will develop several active pharmaceutical ingredients and finished products for the Chinese market and will engage the Company to manufa… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AMPH-DEBT | Debt stack $619.7M | 90% | Market cache reports total debt of $619.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AMPH-OWNER-AMERICAN-CENTURY-COMPANIES-INC | AMERICAN CENTURY COMPANIES INC | 95% | 13F/ownership overlay lists AMERICAN CENTURY COMPANIES INC; shares held 1,017,538; value $19.9B; as of 2026-03-31. |
| AMPH-OWNER-MARSHALL-WACE-LLP | MARSHALL WACE, LLP | 95% | 13F/ownership overlay lists MARSHALL WACE, LLP; shares held 1,025,640; value $20.1B; as of 2026-03-31. |
| AMPH-OWNER-TD-ASSET-MANAGEMENT-INC | TD Asset Management Inc | 95% | 13F/ownership overlay lists TD Asset Management Inc; shares held 1,541,044; value $30.2B; as of 2026-03-31. |
| AMPH-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 5,421,343; ownership 12.74%; value $106.2B; as of 2026-03-31. |
| AMPH-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 3,087,310; value $60.5B; as of 2026-03-31. |
| AMPH-OWNER-DIMENSIONAL-FUND-ADVISORS-LP | DIMENSIONAL FUND ADVISORS LP | 95% | 13F/ownership overlay lists DIMENSIONAL FUND ADVISORS LP; shares held 2,027,947; value $39.7B; as of 2026-03-31. |
| AMPH-OWNER-STATE-STREET-CORP | STATE STREET CORP | 95% | 13F/ownership overlay lists STATE STREET CORP; shares held 1,607,515; value $31.5B; as of 2026-03-31. |
| AMPH-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 1,586,647; value $39.4B; as of 2026-03-31. |
| AMPH-OWNER-FULLER-THALER-ASSET-MANAGEMENT-INC | FULLER & THALER ASSET MANAGEMENT, INC. | 95% | 13F/ownership overlay lists FULLER & THALER ASSET MANAGEMENT, INC.; shares held 1,395,139; value $27.3B; as of 2026-03-31. |
| AMPH-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | GEODE CAPITAL MANAGEMENT, LLC | 95% | 13F/ownership overlay lists GEODE CAPITAL MANAGEMENT, LLC; shares held 976,650; value $19.1B; as of 2026-03-31. |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Liawatidewi Yakob | EVP CORP ADMIN CENTER | sell | 1870 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | option_exercise | 5000 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | William J. Peters | CFO, EVP & TREASURER | option_exercise | 3297 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhang Jack Y. | CEO & CHIEF SCIENTIFIC OFFICER | sell | 7773 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | sell | 1357 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhang Jack Y. | CEO & CHIEF SCIENTIFIC OFFICER | sell | 7773 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Liawatidewi Yakob | EVP CORP ADMIN CENTER | sell | 1144 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | sell | 1357 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | William J. Peters | CFO, EVP & TREASURER | sell | 2146 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | William J. Peters | CFO, EVP & TREASURER | sell | 1744 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhang Jack Y. | CEO & CHIEF SCIENTIFIC OFFICER | sell | 5769 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | sell | 1124 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Liawatidewi Yakob | EVP CORP ADMIN CENTER | sell | 965 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | William J. Peters | CFO, EVP & TREASURER | sell | 1744 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Liawatidewi Yakob | EVP CORP ADMIN CENTER | sell | 965 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | sell | 1124 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhang Jack Y. | CEO & CHIEF SCIENTIFIC OFFICER | sell | 5769 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | sell | 1225 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | Zhang Jack Y. | CEO & CHIEF SCIENTIFIC OFFICER | sell | 9784 shares |
| AMPH | Amphastar Pharmaceuticals, Inc. | 82% | William J. Peters | CFO, EVP & TREASURER | option_exercise | 1973 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | 100.00 | 1 | ['customer', 'supplier'] |
| HALO | Halozyme Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| MCK | McKesson Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| CAH | Cardinal Health, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| MNKD | MannKind Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| HLNCF | Haleon plc | 100.00 | 2 | |
| HANXIN | HANXIN | 63.48 | 1 | ['receiving'] |
| BFRGW | BullFrog AI Holdings, Inc. | 50.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 50.00 | 2 | |
| ASBPW | Aspire Biopharma Holdings, Inc. | 50.00 | 2 | |
| ARQQW | Arqit Quantum Inc. | 50.00 | 2 | |
| AYTU | Aytu BioPharma, Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| BCDRF | Banco Santander, S.A. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| CINGW | Cingulate Inc. | 50.00 | 2 | |
| AMZE | Amaze Holdings, Inc. | 50.00 | 2 | |
| BLTE | Belite Bio, Inc | 50.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 50.00 | 2 |